GSK 269962
Tocris Bioscience, part of Bio-Techne | Catalog # 4009
Potent and selective ROCK inhibitor
Key Product Details
Description
Potent and selective ROCK inhibitor
Product Description
GSK 269962 is a potent Rho kinase (ROCK) inhibitor (IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively). Displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM); lowers blood pressure in a rat model of hypertension.Licensing Information
Sold for research purposes under agreement from GlaxoSmithKline.Product Specifications
Molecular Weight
570.60
Formula
C29H30N8O5
Storage
Store at +4°C
Purity
≥98% (HPLC)
Chemical Name
N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]benzamide
CAS Number
850664-21-0
PubChem ID
16095342
InChI Key
YOVNFNXUCOWYSG-UHFFFAOYSA-N
SMILES
CCN(C(C4=NON=C4N)=N3)C1=C3C=NC(OC2=CC(NC(C5=CC=C(OCCN6CCOCC6)C=C5)=O)=CC=C2)=C1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 57.06 | 100 | |
| Ethanol | 5.71 | 10 with gentle warming |
Preparing Stock Solutions
for GSK 269962
The following data is based on the product molecular weight 570.60
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.75 mL | 8.76 mL | 17.53 mL |
| 5 mM | 0.35 mL | 1.75 mL | 3.51 mL |
| 10 mM | 0.18 mL | 0.88 mL | 1.75 mL |
| 50 mM | 0.04 mL | 0.18 mL | 0.35 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Stavenger Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J.Med.Chem. 2007 PMID: 17201404
- Doe Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J.Pharmacol.Exp.Ther. 2007 PMID: 17018693
Product Specific Notices for GSK 269962
For research use only
Loading...
Loading...